Braveheart Bio (BRVE) vs Schrodinger (SDGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Schrodinger is the larger company by market cap ($1.72 billion vs $1.67 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BRVE | SDGR |
|---|---|---|
| Share price | $20.39 | $22.93 |
| Market cap | $1.67B | $1.72B |
| 1-day change | +5.81% | -12.95% |
| YTD return | — | +28.24% |
| 1-year return | — | +39.22% |
| 5-year return | — | -42.01% |
| EPS (TTM) | $-6.59 | $-0.79 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $255.87M |
| Revenue growth (YoY) | — | +23.29% |
| Net income (latest FY) | — | $-103.27M |
| Gross margin | — | 55.74% |
| Operating margin | — | -65.23% |
| Net margin | — | -40.36% |
| 52-week high | $32.00 | $34.00 |
| 52-week low | $16.70 | $10.95 |
| Distance from 52-week high | -36.28% | -32.56% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +123.15% | +46.40% |
| Average volume | 491.27K | 2.08M |
| Shares outstanding | 82.07M | 65.91M |
| Employees | 49 | 850 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Braveheart Bio
BRVE stock →Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
BRVE vs SDGR FAQ
Which is bigger, Braveheart Bio or Schrodinger?
Schrodinger (SDGR) is larger, with a market capitalization of $1.72B compared with $1.67B for Braveheart Bio (BRVE).
Are Braveheart Bio and Schrodinger in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.